Skip to content

The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Clinical trials

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Recruiting nowPhase 2Randomised

What this trial is trying to do

The researchers are testing whether cancer-directed treatment delivered at home, with virtual and home-health support, can provide a similar treatment experience to receiving it in a clinic. The intervention changes where care is delivered rather than how the cancer drug works.

Compared with clinic-based care, home treatment may reduce travel, time away from family, and financial and emotional strain, and may help people stay on treatment. The trial is measuring patients’ reported access to cancer care and remote expertise, rather than whether the cancer grows more slowly or people live longer.

Worth knowing: The main outcome is a patient-reported care experience, so this trial will not by itself show that home treatment improves tumour control or survival.

Written from the trial's own registry entry to explain what the researchers are testing and why. Nothing here is a result — this trial has not reported one — and it is not a view on whether the treatment works or on whether it would suit you.

The trial at a glance
Registry number NCT05969860
Recruitment Recruiting now
Phase Phase 2
Design randomised, open label
Taking part 220 people (planned)
Who can join aged 18 Years and over
Run by Mayo Clinic
Started
Main results expected
Record last updated

What is being tested

  • Procedure Clinical Encounter
  • Other Home Health Encounter
  • Other Quality-of-Life Assessment
  • Other Questionnaire Administration

What it is measuring

Mean patient-reported rating of Cancer Connected Access and Remote Expertise

This is the trial's main question — the one it is designed and sized to answer. Anything else it reports is a secondary finding, and secondary findings are far more likely to be chance.

Phase 2. Tests whether the treatment works well enough to be worth a larger trial. Usually too small to prove it changes survival.

How the researchers describe it

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.

Written by the trial’s sponsor, quoted from its ClinicalTrials.gov record.

What this trial is looking for

Genotype

  • HER2 positive

Read automatically from the criteria below, to make the list searchable. It is a summary of what the text mentions, not a decision about whether you qualify — and where the two disagree, the criteria are right and this is wrong.

Who the trial is looking for

Inclusion Criteria

  • Female or male patients with histologically confirmed malignancy. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required.
  • Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines.
  • Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified.

This is an extract. Whether you qualify is decided by the trial team against the full criteria, not by reading this page. Read the full eligibility criteria

Where it is running

Running at 2 sites. Listed in: United States.

Individual hospitals, and whether each is currently open, are listed on the registry record. Sites open and close throughout a trial.

Worth asking your oncology team

Being listed here is not a recommendation, and no one page can tell you whether a trial is right for you. These are the questions it raises.

  • Is this trial open at a hospital I could realistically travel to?
  • Given my stage, my previous treatment and my tumour's molecular profile, would I be eligible?
  • What would I be giving up by joining — is the comparison arm the treatment I would otherwise be having?
  • What is already known about the safety of what is being tested?

The source

Registry record NCT05969860, registered by Mayo Clinic on ClinicalTrials.gov, a public database run by the US National Library of Medicine. The details on this page come from that record and are only ever as current as the sponsor has kept it.

This is a listing of a registered clinical trial, reproduced for information. It is not a recommendation, this site has no connection to the trial or its sponsor, and being listed here says nothing about whether the treatment works. Talk to your own oncology team before pursuing any trial.

This article summarises published research for general information. It is not medical advice, and it is not a substitute for a conversation with your own oncology team, who know your case. Do not start, stop, or change any treatment or supplement on the basis of what you read here.


Other trials being tracked

466 trials

See all trials